NBI-1076968


NBI-1076968 is a selective muscarinic acetylcholine M4 receptor antagonist which is under development by Neurocrine Biosciences for the treatment of movement disorders. It is orally active.

Pharmacology

Along with the earlier drugs PD-0298029 and PD-102,807, NBI-1076968 is among the only selective M4 receptor antagonists to have been developed to date. However, in contrast to NBI-1076968, the earlier selective antagonists have not had optimal drug-like properties for development as pharmaceutical drugs.

Clinical trials

As of September 2024, NBI-1076968 is in phase 1 clinical trials for treatment of movement disorders. The drug is under development by Neurocrine Biosciences. It was first described in 2024.